Clinsys Redefines Resource Services with the Launch of Clinsys ALTERNA
Clinsys Clinical Researchannounced the launch of Clinsys ALTERNA for customized Phase I–IV alternative solutions.
Bedminster, NJ-April 10, 2008-Clinsys Clinical Research, a therapeutically focused global contract research organization, today announced the launch of Clinsys ALTERNA, which utilizes its Global Project Solution® (Clinsys GPS®) to augment clinical resource services. The new division demonstrates Clinsys’ commitment to aligning its service offerings with its sponsors’ and the life sciences industry’s continuously evolving staffing needs.
Clinsys ALTERNA provides customized Phase I–IV clinical trial alternative solutions to the conventional outsourcing model. The division is a core element of Clinsys GPS, a unique, highly effective, and proven integrated project management solution that brings the sponsor and the Clinsys project teams together to collaborate and agree on all aspects of the clinical study-before, during, and after-to ensure the project’s success.
“Clinsys ALTERNA provides a targeted and flexible clinical resourcing model that adapts to best serve a sponsor’s trial management needs,” said David E. Williams, chief executive officer of Clinsys. “We devoted the time and energy required to approach the evolution of resourcing in an innovative way that both maximizes efficiencies and decreases deliverable timelines.”
Drawing on extensive clinical research experience, Clinsys ALTERNA delivers a custom-designed, time-sensitive clinical solution that enables sponsors to engage its services in site management, clinical monitoring, project management, drug safety, regulatory, and medical writing on a contract basis. Clinsys ALTERNA combines therapeutic expertise, clinical screening, performance reviews, site references, and global reach to offer clients the most dependable and comprehensive alternative approach to their trial needs. Visit clinsysalterna.com for more information.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
